Regeneron Pharmaceuticals, Inc. (REGN) To Go Ex-Dividend on May 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Wednesday, April 29th. Shareholders of record on Wednesday, May 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, June 4th. This represents a c) dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% meaning its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $41.51 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 9.1%.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $698.25 on Monday. The stock’s fifty day moving average price is $744.69 and its two-hundred day moving average price is $746.09. The company has a market cap of $73.82 billion, a P/E ratio of 17.01, a P/E/G ratio of 1.55 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.22 EPS. As a group, analysts expect that Regeneron Pharmaceuticals will post 37.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on REGN shares. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. TD Cowen increased their target price on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Oppenheimer reissued an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $800.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, April 23rd. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $826.59.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.